Литература
1. http://www.genet.sickkids.on.ca/cftr
2. Castellani C., Cuppens H., Macek M., Jr., et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J. Cyst. Fibros. 2008 May; 7 (3): 179-196.
3. Pettit R.S. Cystic Fibrosis Transmembrane Conductance Regulator–Modifying Medications. Ann Pharmacother. 2012 Jul-Aug; 46 (7-8): 1065-1075.
4. Zielenski, J. Genotype and phenotype in cystic fibrosis. Respiration. 2000; 67 (2): 117-133.
5. Mishra A., Greaves R., Massie J.. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era. Clin. Biochem. Rev. 2005 Nov; 26 (4): 135-153.
6. Pettit R.S., Fellner C. CFTR Modulators for the Treatment of Cystic Fibrosis. P&T®. 2014 Jul; 39 (7): 500-511.
7. Griesenbach U., Alton E.W. Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction. F1000 Prime Rep. 2015 May 27; 7: 64. (http://f1000.com/prime/ reports/m/7/64).
8. Marson F.A., Bertuzzo C.S., Ribeiro J.D. Classification of CFTR mutation classes Lancet Respir Med. 2016 Aug; 4 (8): e37-8.
9. De Boek K., Amaral M.D. Progress in therapies for cystic fibrosis lancet Respir Med. 2016 Aug; 4 (8): 662-74.
10. Borowitz D., Durie P.R., Clarke L.L., et al. Gastrointestinal outcomes and confounders in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 2005 Sep; 41 (3): 273-285.
11. Ahmed N., Corey M., Forstner G. et al. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut. 2003 Aug; 52 (8): 1159-1164.
12. Koch C., Cuppens H., Rainisio M., et al. European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulmonol. 2001 Jan; 31 (1): 1-12.
13. Koch C. Early Infection and Progression of Cystic Fibrosis Lung Disease. Pediatr Pulmonol. 2002 Sep; 34 (3): 232-236.
14. Smyth A.R., Bell S.C., Bojcin S. et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J. Cyst. Fibros. 2014 May; 13 Suppl. 1: S23-42.
15. http://www.cftr2.org
16. Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015. May; 17 (5): 405-424.
17. Wallis Y., Payne S., McAnulty C., et al. Practice Guideline for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics. Available at https://www.acgs.uk.com
18. Clinical Genomics. A Guide to Clinical Next Generation Sequencing. Edited by S. Kulkarni, J. Pfeifer. Elsevier Inc., Academic Press, London, UK, 2015, p. 470. ISBN: 978-0-12-404748-8.
19. Quintáns B., Ordóñez-Ugalde A., Cacheiro P., et al. Carracedo, A., Sobrido, M.J. Medical genomics: The intricate path from genetic variant identification to clinical interpretation. Appl. Transl. Genom. 2014 Jun 16; 3 (3): 60-67.
20. Kerem E., Conway S., Elborn S., Heijerman H. Standards of care for patients with cystic fibrosis:a European consensus. J. Cyst. Fibros. 2005 Mar; 4 (1): 7-26.
21. Farrell P.M., Rosenstein B.J., White T.B., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J. Pediatr. 2008 Aug; 153 (2): S4-S14.
